• Users Online: 123
  • Home
  • Print this page
  • Email this page


 
 Table of Contents  
ARTICLE
Year : 2016  |  Volume : 5  |  Issue : 5  |  Page : 31-32

Reaching consensus on drug resistance conferring mutations (Part 1)


Emerging Bacterial pathogens Unit, San Raffaele Scientific Institute, via Olgettina 60, Milan, Italy

Date of Web Publication17-Feb-2017

Correspondence Address:
Daniela M Cirillo
Emerging Bacterial pathogens Unit, San Raffaele Scientific Institute, via Olgettina 60, Milan
Italy
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.1016/j.ijmyco.2016.09.062

Rights and Permissions
  Abstract 


Objective/background: Molecular-based, rapid drug-susceptibility tests are needed to guide the appropriate use of new drugs and new therapeutic regimens at the programmatic level, and to prevent a further increase in the incidence of drug-resistant tuberculosis (TB). Experts have recognized the need for a global, curated, and standardized analysis and data-sharing platform that provides a one-stop data source for clinically relevant genotypic and phenotypic information on Mycobacterium tuberculosis.
Methods: To this purpose, the Relational Sequencing TB Data Platform (ReSeqTB) consortium has critically reviewed the most inclusive set of published data on mutations associated with drug resistance in M. tuberculosis to date, and has graded a comprehensive list of globally prevalent mutations based on the strength of their association with drug resistance.
Results and Conclusions: ReSeqTB serves as a single repository for the compilation, curation, and validation of existing and newly created sequences and metadata on M. tuberculosis strains and will use the currently reviewed data set, validated by international experts, as a starting point until sufficient new sequence data are accumulated. This initiative is supported by a global partnership of academic institutions, public health agencies, and nongovernmental organizations including the Critical Path Institute, FIND, the World Health Organization, the New Diagnostics Working Group, the U.S. Centers for Disease Control and Prevention, and the National Institute of Allergy and Infectious Diseases and it is financially supported by the Bill & Melinda Gates Foundation. Key strengths of the ReSeqTB Database include the following:

  • A user-friendly interface designed for nonexpert or expert operability.
  • A standardized and validated analysis pipeline for variant analyses of M. tuberculosis next-generation sequencing (NGS) data.
  • Access to data beyond the published literature with dynamic and iterative updates of new data generated by global surveillance and clinical trials.
  • A well-developed legal structure to ensure intellectual property rights and data ownership remain with contributors.
  • A structured data-sharing architecture to restrict access to sensitive or unpublished data sets.
  • Metadata standardization using CDISC: supports global, platform-independent data standards that enable information system interoperability.
  • An emphasis on data quality and rigorous, expert curation with multiple quality control checks for whole-genome sequencing and other metadata.
  • Validation of NGS analysis output by an expert committee with grading of resistance conferring mutations based on rigorous statistical standards.
  • Regulatory-compliant analysis pipeline and database architecture.

Successful execution of such an extensive database platform requires substantial collaboration from scientists investigating the genetic basis for drug resistance worldwide, and from developers with expertise in database design and implementation.

Keywords: Conferring mutations, Drug resistance, Molecular-based, Rapid drug-susceptibility tests


How to cite this article:
Cirillo DM, Miotto P, Tagliani E. Reaching consensus on drug resistance conferring mutations (Part 1). Int J Mycobacteriol 2016;5, Suppl S1:31-2

How to cite this URL:
Cirillo DM, Miotto P, Tagliani E. Reaching consensus on drug resistance conferring mutations (Part 1). Int J Mycobacteriol [serial online] 2016 [cited 2019 Nov 20];5, Suppl S1:31-2. Available from: http://www.ijmyco.org/text.asp?2016/5/5/31/200466




  Conflicts of interest Top


All authors declare no conflicts of interest.





This article has been cited by
1 Application of Next-Generation Sequencing in Public Health Epidemiology and Outbreak Investigation
Anthony Tran,Marie-Claire Rowlinson
Advances in Molecular Pathology. 2019; 2(1): 89
[Pubmed] | [DOI]
2 Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?
Kwok-Chiu Chang,Wing-Wai Yew,Ying Zhang
Antimicrobial Agents and Chemotherapy. 2017; 62(1): e01907-17
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Conflicts of int...

 Article Access Statistics
    Viewed557    
    Printed26    
    Emailed0    
    PDF Downloaded56    
    Comments [Add]    
    Cited by others 2    

Recommend this journal